1
|
Chiu YS, Wu KJ, Yu SJ, Wu KL, Wang YS, Lin J, Chu CY, Chen S, Chen H, Hsu SC, Wang Y, Chen YH. Peptide immunization against the C-terminal of alpha-synuclein reduces locomotor activity in mice overexpressing alpha-synuclein. PLoS One 2023; 18:e0291927. [PMID: 37733672 PMCID: PMC10513202 DOI: 10.1371/journal.pone.0291927] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2023] [Accepted: 09/09/2023] [Indexed: 09/23/2023] Open
Abstract
Abnormal accumulation of alpha-synuclein (αSyn) in the remaining nigra dopaminergic neurons is a common neuropathological feature found in patients with Parkinson's disease (PD). Antibody-based immunotherapy has been considered a potential approach for PD treatment. This study aims to investigate the effectiveness of active immunization against αSyn in a mouse model of PD. Adult mice were immunized with or without a synthetic peptide containing the C-terminal residues of human αSyn and activation epitopes, followed by an intranigral injection of adeno-associated virus vectors for overexpressing human αSyn. Upon the peptide injection, αSyn-specific antibodies were raised, accompanied by degeneration of dopaminergic neurons and motor deficits. Furthermore, the induction of neuroinflammation was postulated by the elevation of astroglial and microglial markers in the immunized mice. Instead of lessening αSyn toxicity, this peptide vaccine caused an increase in the pathogenic species of αSyn. Our data demonstrated the potential adverse effects of active immunization to raise antibodies against the C-terminal fragment of αSyn. This drawback highlights the need for further investigation to weigh the pros and cons of immunotherapy in PD. Applying the αSyn C-terminal peptide vaccine for PD treatment should be cautiously exercised. This study provides valuable insights into the intricate interplay among immune intervention, αSyn accumulation, and neurodegeneration.
Collapse
Affiliation(s)
- Yu-Sung Chiu
- Department of Life Science, Fu-Jen Catholic University, New Taipei City, Taiwan
| | - Kuo-Jen Wu
- National Health Research Institutes, Center for Neuropsychiatric Research, Zhunan, Taiwan
- School of Pharmacy, College of Pharmacy, China Medical University, Taichung, Taiwan
| | - Seong-Jin Yu
- National Health Research Institutes, Center for Neuropsychiatric Research, Zhunan, Taiwan
| | - Kun-Lieh Wu
- Department of Electrical Engineering of I-Shou University, Kaohsiung, Taiwan
| | - Yu-Syuan Wang
- National Health Research Institutes, Center for Neuropsychiatric Research, Zhunan, Taiwan
| | - Jing Lin
- Department of Life Science, Fu-Jen Catholic University, New Taipei City, Taiwan
| | - Chia-Ying Chu
- Department of Life Science, Fu-Jen Catholic University, New Taipei City, Taiwan
| | - Shuchun Chen
- Department of Life Science, Fu-Jen Catholic University, New Taipei City, Taiwan
- National Health Research Institutes, Center for Neuropsychiatric Research, Zhunan, Taiwan
| | - Hsi Chen
- National Health Research Institutes, Center for Neuropsychiatric Research, Zhunan, Taiwan
| | - Shu-Ching Hsu
- Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan
- Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung City, Taiwan
- PhD Program in Tissue Engineering and Regenerative Medicine, National Chung Hsing University, Taichung City, Taiwan
- Graduate Institute of Biomedical Science, China Medical University, Taichung City, Taiwan
- Immunology Research and Development Center, China Medical University, Taichung City, Taiwan
- Department of Life Sciences, Tzu Chi University, Hualien, Taiwan
| | - Yun Wang
- National Health Research Institutes, Center for Neuropsychiatric Research, Zhunan, Taiwan
| | - Yun-Hsiang Chen
- Department of Life Science, Fu-Jen Catholic University, New Taipei City, Taiwan
- National Health Research Institutes, Center for Neuropsychiatric Research, Zhunan, Taiwan
| |
Collapse
|
2
|
Akache B, Read AJ, Dudani R, Harrison BA, Williams D, Deschatelets L, Jia Y, Chandan V, Stark FC, Agbayani G, Makinen SR, Hemraz UD, Lam E, Régnier S, Zou W, Kirkland PD, McCluskie MJ. Sulfated Lactosyl Archaeol Archaeosome-Adjuvanted Vaccine Formulations Targeting Rabbit Hemorrhagic Disease Virus Are Immunogenic and Efficacious. Vaccines (Basel) 2023; 11:1043. [PMID: 37376432 DOI: 10.3390/vaccines11061043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Revised: 05/24/2023] [Accepted: 05/27/2023] [Indexed: 06/29/2023] Open
Abstract
Vaccines play an important role in maintaining human and animal health worldwide. There is continued demand for effective and safe adjuvants capable of enhancing antigen-specific responses to a target pathogen. Rabbit hemorrhagic disease virus (RHDV) is a highly contagious calicivirus that often induces high mortality rates in rabbits. Herein, we evaluated the activity of an experimental sulfated lactosyl archaeol (SLA) archaeosome adjuvant when incorporated in subunit vaccine formulations targeting RHDV. The subunit antigens consisted of RHDV-CRM197 peptide conjugates or recombinant RHDV2 VP60. SLA was able to enhance antigen-specific antibody titers and cellular responses in mice and rabbits. Three weeks following immunization, antigen-specific antibody levels in rabbits vaccinated with RHDV2 VP60 + SLA were significantly higher than those immunized with antigen alone, with geomean titers of 7393 vs. 117. In addition, the SLA-adjuvanted VP60-based formulations were highly efficacious in a rabbit RHDV2 challenge model with up to 87.5% animals surviving the viral challenge. These findings demonstrate the potential utility of SLA adjuvants in veterinary applications and highlight its activity in different types of mammalian species.
Collapse
Affiliation(s)
- Bassel Akache
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Andrew J Read
- Virology Laboratory, Elizabeth Macarthur Agricultural Institute, NSW Department of Primary Industries, Menangle, NSW 2567, Australia
| | - Renu Dudani
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Blair A Harrison
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Dean Williams
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Lise Deschatelets
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Yimei Jia
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Vandana Chandan
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Felicity C Stark
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Gerard Agbayani
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Shawn R Makinen
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Usha D Hemraz
- National Research Council Canada, Aquatic and Crop Resource Development, Montreal, QC H4P 2R2, Canada
| | - Edmond Lam
- National Research Council Canada, Aquatic and Crop Resource Development, Montreal, QC H4P 2R2, Canada
| | - Sophie Régnier
- National Research Council Canada, Aquatic and Crop Resource Development, Montreal, QC H4P 2R2, Canada
| | - Wei Zou
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Peter D Kirkland
- Virology Laboratory, Elizabeth Macarthur Agricultural Institute, NSW Department of Primary Industries, Menangle, NSW 2567, Australia
| | - Michael J McCluskie
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| |
Collapse
|
3
|
Kheirvari M, Liu H, Tumban E. Virus-like Particle Vaccines and Platforms for Vaccine Development. Viruses 2023; 15:1109. [PMID: 37243195 PMCID: PMC10223759 DOI: 10.3390/v15051109] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Revised: 04/25/2023] [Accepted: 04/26/2023] [Indexed: 05/28/2023] Open
Abstract
Virus-like particles (VLPs) have gained a lot of interest within the past two decades. The use of VLP-based vaccines to protect against three infectious agents-hepatitis B virus, human papillomavirus, and hepatitis E virus-has been approved; they are very efficacious and offer long-lasting immune responses. Besides these, VLPs from other viral infectious agents (that infect humans, animals, plants, and bacteria) are under development. These VLPs, especially those from human and animal viruses, serve as stand-alone vaccines to protect against viruses from which the VLPs were derived. Additionally, VLPs, including those derived from plant and bacterial viruses, serve as platforms upon which to display foreign peptide antigens from other infectious agents or metabolic diseases such as cancer, i.e., they can be used to develop chimeric VLPs. The goal of chimeric VLPs is to enhance the immunogenicity of foreign peptides displayed on VLPs and not necessarily the platforms. This review provides a summary of VLP vaccines for human and veterinary use that have been approved and those that are under development. Furthermore, this review summarizes chimeric VLP vaccines that have been developed and tested in pre-clinical studies. Finally, the review concludes with a snapshot of the advantages of VLP-based vaccines such as hybrid/mosaic VLPs over conventional vaccine approaches such as live-attenuated and inactivated vaccines.
Collapse
Affiliation(s)
| | | | - Ebenezer Tumban
- School of Veterinary Medicine, Texas Tech University, Amarillo, TX 79106, USA
| |
Collapse
|
4
|
Immunogenicity of Wild Type and Mutant Hepatitis B Surface Antigen Virus-like Particles (VLPs) in Mice with Pre-Existing Immunity against the Wild Type Vector. Viruses 2023; 15:v15020313. [PMID: 36851527 PMCID: PMC9963944 DOI: 10.3390/v15020313] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2022] [Revised: 01/18/2023] [Accepted: 01/18/2023] [Indexed: 01/24/2023] Open
Abstract
Virus-like particles (VLPs), composed of the small hepatitis B virus surface antigen (HBsAgS), are the antigenic components of the hepatitis B virus (HBV) vaccine and represent the backbones for a chimeric anti-malaria vaccine and various vaccine candidates. Biological vectors have to face pre-existing anti-vector immune responses due to previous immune exposure. Vector recognition after natural infections or vaccinations can result in unwarranted outcomes, with compromising effects on clinical outcomes. In order to evaluate the impact of a pre-existing anti-HBsAgS immune response, we developed mutant VLPs composed of subunits with reduced HBsAgS-specific antigenicity. The insertion of a Plasmodium falciparum circumsporozoite protein (CSP)-derived epitope as a read-out allowed the assessment of wild type (wt) and mutant VLPs in the context of a pre-existing immune response. Mutant and wt VLP platforms with a CSP-epitope insert are immunogenic and have the ability to generate anti-CSP antibody responses in both naïve BALB/c mice and mice with a pre-existing anti-HBsAgS immune response, but with superior anti-CSP responses in mice with a pre-existing immunity. The data indicate that previous HBsAgS exposure facilitates enhanced antibody responses against foreign epitopes delivered by the HBsAgS platform, and, in this context, the state of immune sensitization alters the outcome of subsequent vaccinations.
Collapse
|
5
|
Shi R, Zeng J, Xu L, Wang F, Duan X, Wang Y, Wu Z, Yu D, Huang Q, Yao YG, Yan J. A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core. EBioMedicine 2022; 85:104297. [PMID: 36206623 PMCID: PMC9530591 DOI: 10.1016/j.ebiom.2022.104297] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2022] [Revised: 09/20/2022] [Accepted: 09/20/2022] [Indexed: 11/07/2022] Open
Abstract
Background Increasing severe morbidity and mortality by simultaneous or sequential infections with SARS-CoV-2 and influenza A viruses (IAV), especially in the elderly and obese patients, highlight the urgency of developing a combination vaccine against COVID-19 and influenza. Methods Self-assembling SARS-CoV-2 RBD-trimer and Influenza H1N1 HA1-trimer antigens were constructed, upon the stable fusion core in post-fusion conformation. Immunogenicity of SARS-CoV-2 RBD-trimer vaccine and H1N1 HA1-trimer antigens candidates were evaluated in mice. Protection efficacy of a combination vaccine candidate against SARS-CoV-2 and IAV challenge was identified using the K18-hACE2 mouse model. Findings Both the resultant RBD-trimer for SARS-CoV-2 and HA1-trimer for H1N1 influenza fully exposed receptor-binding motifs (RBM) or receptor-binding site (RBS). Two-dose RBD-trimer induced significantly higher binding and neutralizing antibody titers, and also a strong Th1/Th2 balanced cellular immune response in mice. Similarly, the HA1-trimer vaccine was confirmed to exhibit potent immunogenicity in mice. A combination vaccine candidate, composed of RBD-trimer and HA1-trimer, afforded high protection efficacy in mouse models against stringent lethal SARS-CoV-2 and homogenous H1N1 influenza co-infection, characterized by 100% survival rate. Interpretation Our results represent a proof of concept for a combined vaccine candidate based on trimerized receptor binding domain against co-epidemics of COVID-19 and influenza. Funding This project was funded by the Strategic Priority Research Program of CAS (XDB29040201), the National Natural Science Foundation of China (81830050, 81901680, and 32070569) and China Postdoctoral Science Foundation (2021M703450).
Collapse
Affiliation(s)
- Rui Shi
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China
| | - Jiawei Zeng
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China,University of Chinese Academy of Sciences, Beijing 100049, China
| | - Ling Xu
- Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences & Yunnan Province, and KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650201, China,Kunming National High-level Biosafety Research Center for Non-Human Primates, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650107, China
| | - Fengze Wang
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China,University of Chinese Academy of Sciences, Beijing 100049, China
| | - Xiaomin Duan
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China,University of Chinese Academy of Sciences, Beijing 100049, China
| | - Yue Wang
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China,University of Chinese Academy of Sciences, Beijing 100049, China
| | - Zheng Wu
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China,Institute of Physical Science and Information, Anhui University, Hefei, 230039, China
| | - Dandan Yu
- Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences & Yunnan Province, and KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650201, China,Kunming National High-level Biosafety Research Center for Non-Human Primates, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650107, China
| | - Qingrui Huang
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China,Corresponding authors.
| | - Yong-Gang Yao
- Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences & Yunnan Province, and KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650201, China,Kunming National High-level Biosafety Research Center for Non-Human Primates, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650107, China,National Resource Center for Non-Human Primates, National Research Facility for Phenotypic & Genetic Analysis of Model Animals (Primate Facility), Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650107, China,Kunming College of Life Science, University of Chinese Academy of Sciences, Kunming, Yunnan 650204, China,Corresponding authors.
| | - Jinghua Yan
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China,University of Chinese Academy of Sciences, Beijing 100049, China,Corresponding authors.
| |
Collapse
|
6
|
Palmieri E, Kis Z, Ozanne J, Di Benedetto R, Ricchetti B, Massai L, Carducci M, Oldrini D, Gasperini G, Aruta MG, Rossi O, Kontoravdi C, Shah N, Mawas F, Micoli F. GMMA as an Alternative Carrier for a Glycoconjugate Vaccine against Group A Streptococcus. Vaccines (Basel) 2022; 10:vaccines10071034. [PMID: 35891202 PMCID: PMC9324507 DOI: 10.3390/vaccines10071034] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2022] [Revised: 06/20/2022] [Accepted: 06/23/2022] [Indexed: 11/16/2022] Open
Abstract
Group A Streptococcus (GAS) causes about 500,000 annual deaths globally, and no vaccines are currently available. The Group A Carbohydrate (GAC), conserved across all GAS serotypes, conjugated to an appropriate carrier protein, represents a promising vaccine candidate. Here, we explored the possibility to use Generalized Modules for Membrane Antigens (GMMA) as an alternative carrier system for GAC, exploiting their intrinsic adjuvant properties. Immunogenicity of GAC-GMMA conjugate was evaluated in different animal species in comparison to GAC-CRM197; and the two conjugates were also compared from a techno-economic point of view. GMMA proved to be a good alternative carrier for GAC, resulting in a higher immune response compared to CRM197 in different mice strains, as verified by ELISA and FACS analyses. Differently from CRM197, GMMA induced significant levels of anti-GAC IgG titers in mice also in the absence of Alhydrogel. In rabbits, a difference in the immune response could not be appreciated; however, antibodies from GAC-GMMA-immunized animals showed higher affinity toward purified GAC antigen compared to those elicited by GAC-CRM197. In addition, the GAC-GMMA production process proved to be more cost-effective, making this conjugate particularly attractive for low- and middle-income countries, where this pathogen has a huge burden.
Collapse
Affiliation(s)
- Elena Palmieri
- GSK Vaccines Institute for Global Health (GVGH), Via Fiorentina 1, 53100 Siena, Italy; (E.P.); (R.D.B.); (B.R.); (L.M.); (M.C.); (D.O.); (G.G.); (M.G.A.); (O.R.)
| | - Zoltán Kis
- The Sargent Centre for Process Systems Engineering, Department of Chemical Engineering, Imperial College London, South Kensington Campus, London SW7 2AZ, UK; (Z.K.); (C.K.); (N.S.)
- Department of Chemical and Biological Engineering, The University of Sheffield, Mappin Street, Sheffield S1 3JD, UK
| | - James Ozanne
- The National Institute for Biological Standards and Control (NIBSC), South Mimms EN6 3QG, UK; (J.O.); (F.M.)
| | - Roberta Di Benedetto
- GSK Vaccines Institute for Global Health (GVGH), Via Fiorentina 1, 53100 Siena, Italy; (E.P.); (R.D.B.); (B.R.); (L.M.); (M.C.); (D.O.); (G.G.); (M.G.A.); (O.R.)
| | - Beatrice Ricchetti
- GSK Vaccines Institute for Global Health (GVGH), Via Fiorentina 1, 53100 Siena, Italy; (E.P.); (R.D.B.); (B.R.); (L.M.); (M.C.); (D.O.); (G.G.); (M.G.A.); (O.R.)
| | - Luisa Massai
- GSK Vaccines Institute for Global Health (GVGH), Via Fiorentina 1, 53100 Siena, Italy; (E.P.); (R.D.B.); (B.R.); (L.M.); (M.C.); (D.O.); (G.G.); (M.G.A.); (O.R.)
| | - Martina Carducci
- GSK Vaccines Institute for Global Health (GVGH), Via Fiorentina 1, 53100 Siena, Italy; (E.P.); (R.D.B.); (B.R.); (L.M.); (M.C.); (D.O.); (G.G.); (M.G.A.); (O.R.)
| | - Davide Oldrini
- GSK Vaccines Institute for Global Health (GVGH), Via Fiorentina 1, 53100 Siena, Italy; (E.P.); (R.D.B.); (B.R.); (L.M.); (M.C.); (D.O.); (G.G.); (M.G.A.); (O.R.)
| | - Gianmarco Gasperini
- GSK Vaccines Institute for Global Health (GVGH), Via Fiorentina 1, 53100 Siena, Italy; (E.P.); (R.D.B.); (B.R.); (L.M.); (M.C.); (D.O.); (G.G.); (M.G.A.); (O.R.)
| | - Maria Grazia Aruta
- GSK Vaccines Institute for Global Health (GVGH), Via Fiorentina 1, 53100 Siena, Italy; (E.P.); (R.D.B.); (B.R.); (L.M.); (M.C.); (D.O.); (G.G.); (M.G.A.); (O.R.)
| | - Omar Rossi
- GSK Vaccines Institute for Global Health (GVGH), Via Fiorentina 1, 53100 Siena, Italy; (E.P.); (R.D.B.); (B.R.); (L.M.); (M.C.); (D.O.); (G.G.); (M.G.A.); (O.R.)
| | - Cleo Kontoravdi
- The Sargent Centre for Process Systems Engineering, Department of Chemical Engineering, Imperial College London, South Kensington Campus, London SW7 2AZ, UK; (Z.K.); (C.K.); (N.S.)
| | - Nilay Shah
- The Sargent Centre for Process Systems Engineering, Department of Chemical Engineering, Imperial College London, South Kensington Campus, London SW7 2AZ, UK; (Z.K.); (C.K.); (N.S.)
| | - Fatme Mawas
- The National Institute for Biological Standards and Control (NIBSC), South Mimms EN6 3QG, UK; (J.O.); (F.M.)
| | - Francesca Micoli
- GSK Vaccines Institute for Global Health (GVGH), Via Fiorentina 1, 53100 Siena, Italy; (E.P.); (R.D.B.); (B.R.); (L.M.); (M.C.); (D.O.); (G.G.); (M.G.A.); (O.R.)
- Correspondence: ; Tel.: +39-0577-539087
| |
Collapse
|
7
|
Zhu H, Rollier CS, Pollard AJ. Recent advances in lipopolysaccharide-based glycoconjugate vaccines. Expert Rev Vaccines 2021; 20:1515-1538. [PMID: 34550840 DOI: 10.1080/14760584.2021.1984889] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
INTRODUCTION The public health burden caused by pathogenic Gram-negative bacteria is increasingly prominent due to antimicrobial resistance. The surface carbohydrates are potential antigens for vaccines against Gram-negative bacteria. The enhanced immunogenicity of the O-specific polysaccharide (O-SP) moiety of LPS when coupled to a carrier protein may protect against bacterial pathogens. However, because of the toxic lipid A moiety and relatively high costs of O-SP isolation, LPS has not been a popular vaccine antigen until recently. AREAS COVERED In this review, we discuss the rationales for developing LPS-based glycoconjugate vaccines, principles of glycoconjugate-induced immunity, and highlight the recent developments and challenges faced by LPS-based glycoconjugate vaccines. EXPERT OPINION Advances in LPS harvesting, LPS chemical synthesis, and newer carrier proteins in the past decade have propelled LPS-based glycoconjugate vaccines toward further development, through to clinical evaluation. The development of LPS-based glycoconjugates offers a new horizon for vaccine prevention of Gram-negative bacterial infection.
Collapse
Affiliation(s)
- Henderson Zhu
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the National Institute for Health Research (Nihr) Oxford Biomedical Research Centre, Oxford, UK
| | - Christine S Rollier
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the National Institute for Health Research (Nihr) Oxford Biomedical Research Centre, Oxford, UK
| | - Andrew J Pollard
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the National Institute for Health Research (Nihr) Oxford Biomedical Research Centre, Oxford, UK
| |
Collapse
|
8
|
Aebischer A, Wernike K, König P, Franzke K, Wichgers Schreur PJ, Kortekaas J, Vitikainen M, Wiebe M, Saloheimo M, Tchelet R, Audonnet JC, Beer M. Development of a Modular Vaccine Platform for Multimeric Antigen Display Using an Orthobunyavirus Model. Vaccines (Basel) 2021; 9:vaccines9060651. [PMID: 34203630 PMCID: PMC8232151 DOI: 10.3390/vaccines9060651] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2021] [Revised: 06/04/2021] [Accepted: 06/08/2021] [Indexed: 12/15/2022] Open
Abstract
Emerging infectious diseases represent an increasing threat to human and animal health. Therefore, safe and effective vaccines that could be available within a short time frame after an outbreak are required for adequate prevention and control. Here, we developed a robust and versatile self-assembling multimeric protein scaffold particle (MPSP) vaccine platform using lumazine synthase (LS) from Aquifex aeolicus. This scaffold allowed the presentation of peptide epitopes by genetic fusion as well as the presentation of large antigens by bacterial superglue-based conjugation to the pre-assembled particle. Using the orthobunyavirus model Schmallenberg virus (SBV) we designed MPSPs presenting major immunogens of SBV and assessed their efficacy in a mouse model as well as in cattle, a target species of SBV. All prototype vaccines conferred protection from viral challenge infection and the multivalent presentation of the selected antigens on the MPSP markedly improved their immunogenicity compared to the monomeric subunits. Even a single shot vaccination protected about 80% of mice from an otherwise lethal dose of SBV. Most importantly, the MPSPs induced a virtually sterile immunity in cattle. Altogether, LS represents a promising platform for modular and rapid vaccine design.
Collapse
Affiliation(s)
- Andrea Aebischer
- Friedrich-Loeffler-Institut, 17493 Greifswald-Insel Riems, Germany; (A.A.); (K.W.); (P.K.); (K.F.)
| | - Kerstin Wernike
- Friedrich-Loeffler-Institut, 17493 Greifswald-Insel Riems, Germany; (A.A.); (K.W.); (P.K.); (K.F.)
| | - Patricia König
- Friedrich-Loeffler-Institut, 17493 Greifswald-Insel Riems, Germany; (A.A.); (K.W.); (P.K.); (K.F.)
| | - Kati Franzke
- Friedrich-Loeffler-Institut, 17493 Greifswald-Insel Riems, Germany; (A.A.); (K.W.); (P.K.); (K.F.)
| | - Paul J. Wichgers Schreur
- Laboratory of Virology, Wageningen Bioveterinary Research, 8221 RA Lelystad, The Netherlands; (P.J.W.S.); (J.K.)
| | - Jeroen Kortekaas
- Laboratory of Virology, Wageningen Bioveterinary Research, 8221 RA Lelystad, The Netherlands; (P.J.W.S.); (J.K.)
| | - Marika Vitikainen
- VTT Technical Research Centre of Finland Ltd., 02150 Espoo, Finland; (M.V.); (M.W.); (M.S.)
| | - Marilyn Wiebe
- VTT Technical Research Centre of Finland Ltd., 02150 Espoo, Finland; (M.V.); (M.W.); (M.S.)
| | - Markku Saloheimo
- VTT Technical Research Centre of Finland Ltd., 02150 Espoo, Finland; (M.V.); (M.W.); (M.S.)
| | - Ronen Tchelet
- Dyadic Netherland B.V., 6709 PA Wageningen, The Netherlands;
| | | | - Martin Beer
- Friedrich-Loeffler-Institut, 17493 Greifswald-Insel Riems, Germany; (A.A.); (K.W.); (P.K.); (K.F.)
- Correspondence:
| |
Collapse
|
9
|
Effect of Preexisting Immunity to Tetanus Toxoid on the Efficacy of Tetanus Toxoid-Conjugated Heroin Vaccine in Mice. Vaccines (Basel) 2021; 9:vaccines9060573. [PMID: 34205869 PMCID: PMC8229309 DOI: 10.3390/vaccines9060573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Revised: 05/21/2021] [Accepted: 05/24/2021] [Indexed: 11/16/2022] Open
Abstract
Opioid use disorder (OUD) is a serious health problem that has dramatically increased over the last decade. Although current therapies for the management of OUD can be effective, they have limitations. The complementary strategy to combat the opioid crisis is the development of a conjugate vaccine to generate high affinity antibodies in order to neutralize opioids in circulation before reaching the brain. The components of an opioid vaccine include an opioid hapten (6-AmHap) that is conjugated to a carrier protein (tetanus toxoid) with the addition of adjuvants (Army Liposome Formulation adsorbed to aluminum hydroxide-ALFA). There is no consensus in the literature as to whether preexisting immunity to the carrier protein may impact the immunogenicity of the conjugate vaccine by inducing an enhanced or suppressed immune response to the hapten. Here, we investigated whether pre-exposure to tetanus toxoid would affect the immunogenicity and efficacy of the heroin vaccine, TT-6-AmHap. Mice were primed with diphtheria, tetanus, and acellular pertussis (DTaP) vaccine at weeks -4 and -2, then immunized with TT-6-AmHap vaccine at weeks 0, 3, and 6. Using ELISA and behavioral assays, we found that preexisting immunity to tetanus toxoid had no influence on the immunogenicity and efficacy of the TT-6-AmHap vaccine.
Collapse
|
10
|
Zeigler DF, Gage E, Clegg CH. Epitope-targeting platform for broadly protective influenza vaccines. PLoS One 2021; 16:e0252170. [PMID: 34043704 PMCID: PMC8158873 DOI: 10.1371/journal.pone.0252170] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2021] [Accepted: 05/10/2021] [Indexed: 11/18/2022] Open
Abstract
Seasonal influenza vaccines are often ineffective because they elicit strain-specific antibody responses to mutation-prone sites on the hemagglutinin (HA) head. Vaccines that provide long-lasting immunity to conserved epitopes are needed. Recently, we reported a nanoparticle-based vaccine platform produced by solid-phase peptide synthesis (SPPS) for targeting linear and helical protein-based epitopes. Here, we illustrate its potential for building broadly protective influenza vaccines. Targeting known epitopes in the HA stem, neuraminidase (NA) active site, and M2 ectodomain (M2e) conferred 50-75% survival against 5LD50 influenza B and H1N1 challenge; combining stem and M2e antigens increased survival to 90%. Additionally, protein sequence and structural information were employed in tandem to identify alternative epitopes that stimulate greater protection; we report three novel HA and NA sites that are highly conserved in type B viruses. One new target in the HA stem stimulated 100% survival, highlighting the value of this simple epitope discovery strategy. A candidate influenza B vaccine targeting two adjacent HA stem sites led to >104-fold reduction in pulmonary viral load. These studies describe a compelling platform for building vaccines that target conserved influenza epitopes.
Collapse
Affiliation(s)
- David F. Zeigler
- TRIA Bioscience Corp., Seattle, Washington, United States of America
| | - Emily Gage
- TRIA Bioscience Corp., Seattle, Washington, United States of America
| | | |
Collapse
|
11
|
Lainšček D, Fink T, Forstnerič V, Hafner-Bratkovič I, Orehek S, Strmšek Ž, Manček-Keber M, Pečan P, Esih H, Malenšek Š, Aupič J, Dekleva P, Plaper T, Vidmar S, Kadunc L, Benčina M, Omersa N, Anderluh G, Pojer F, Lau K, Hacker D, Correia BE, Peterhoff D, Wagner R, Bergant V, Herrmann A, Pichlmair A, Jerala R. A Nanoscaffolded Spike-RBD Vaccine Provides Protection against SARS-CoV-2 with Minimal Anti-Scaffold Response. Vaccines (Basel) 2021; 9:vaccines9050431. [PMID: 33925446 PMCID: PMC8146944 DOI: 10.3390/vaccines9050431] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Revised: 04/22/2021] [Accepted: 04/25/2021] [Indexed: 02/06/2023] Open
Abstract
The response of the adaptive immune system is augmented by multimeric presentation of a specific antigen, resembling viral particles. Several vaccines have been designed based on natural or designed protein scaffolds, which exhibited a potent adaptive immune response to antigens; however, antibodies are also generated against the scaffold, which may impair subsequent vaccination. In order to compare polypeptide scaffolds of different size and oligomerization state with respect to their efficiency, including anti-scaffold immunity, we compared several strategies of presentation of the RBD domain of the SARS-CoV-2 spike protein, an antigen aiming to generate neutralizing antibodies. A comparison of several genetic fusions of RBD to different nanoscaffolding domains (foldon, ferritin, lumazine synthase, and β-annulus peptide) delivered as DNA plasmids demonstrated a strongly augmented immune response, with high titers of neutralizing antibodies and a robust T-cell response in mice. Antibody titers and virus neutralization were most potently enhanced by fusion to the small β-annulus peptide scaffold, which itself triggered a minimal response in contrast to larger scaffolds. The β-annulus fused RBD protein increased residence in lymph nodes and triggered the most potent viral neutralization in immunization by a recombinant protein. Results of the study support the use of a nanoscaffolding platform using the β-annulus peptide for vaccine design.
Collapse
Affiliation(s)
- Duško Lainšček
- EN-FIST, Centre of Excellence, 1000 Ljubljana, Slovenia; (D.L.); (I.H.-B.); (M.M.-K.); (M.B.)
- Department of Synthetic Biology and Immunology, National Institute of Chemistry, 1000 Ljubljana, Slovenia; (T.F.); (V.F.); (S.O.); (Ž.S.); (P.P.); (H.E.); (Š.M.); (J.A.); (P.D.); (T.P.); (S.V.); (L.K.)
| | - Tina Fink
- Department of Synthetic Biology and Immunology, National Institute of Chemistry, 1000 Ljubljana, Slovenia; (T.F.); (V.F.); (S.O.); (Ž.S.); (P.P.); (H.E.); (Š.M.); (J.A.); (P.D.); (T.P.); (S.V.); (L.K.)
| | - Vida Forstnerič
- Department of Synthetic Biology and Immunology, National Institute of Chemistry, 1000 Ljubljana, Slovenia; (T.F.); (V.F.); (S.O.); (Ž.S.); (P.P.); (H.E.); (Š.M.); (J.A.); (P.D.); (T.P.); (S.V.); (L.K.)
| | - Iva Hafner-Bratkovič
- EN-FIST, Centre of Excellence, 1000 Ljubljana, Slovenia; (D.L.); (I.H.-B.); (M.M.-K.); (M.B.)
- Department of Synthetic Biology and Immunology, National Institute of Chemistry, 1000 Ljubljana, Slovenia; (T.F.); (V.F.); (S.O.); (Ž.S.); (P.P.); (H.E.); (Š.M.); (J.A.); (P.D.); (T.P.); (S.V.); (L.K.)
| | - Sara Orehek
- Department of Synthetic Biology and Immunology, National Institute of Chemistry, 1000 Ljubljana, Slovenia; (T.F.); (V.F.); (S.O.); (Ž.S.); (P.P.); (H.E.); (Š.M.); (J.A.); (P.D.); (T.P.); (S.V.); (L.K.)
- Graduate School of Biomedicine, University of Ljubljana, 1000 Ljubljana, Slovenia
| | - Žiga Strmšek
- Department of Synthetic Biology and Immunology, National Institute of Chemistry, 1000 Ljubljana, Slovenia; (T.F.); (V.F.); (S.O.); (Ž.S.); (P.P.); (H.E.); (Š.M.); (J.A.); (P.D.); (T.P.); (S.V.); (L.K.)
- Graduate School of Biomedicine, University of Ljubljana, 1000 Ljubljana, Slovenia
| | - Mateja Manček-Keber
- EN-FIST, Centre of Excellence, 1000 Ljubljana, Slovenia; (D.L.); (I.H.-B.); (M.M.-K.); (M.B.)
- Department of Synthetic Biology and Immunology, National Institute of Chemistry, 1000 Ljubljana, Slovenia; (T.F.); (V.F.); (S.O.); (Ž.S.); (P.P.); (H.E.); (Š.M.); (J.A.); (P.D.); (T.P.); (S.V.); (L.K.)
| | - Peter Pečan
- Department of Synthetic Biology and Immunology, National Institute of Chemistry, 1000 Ljubljana, Slovenia; (T.F.); (V.F.); (S.O.); (Ž.S.); (P.P.); (H.E.); (Š.M.); (J.A.); (P.D.); (T.P.); (S.V.); (L.K.)
- Graduate School of Biomedicine, University of Ljubljana, 1000 Ljubljana, Slovenia
| | - Hana Esih
- Department of Synthetic Biology and Immunology, National Institute of Chemistry, 1000 Ljubljana, Slovenia; (T.F.); (V.F.); (S.O.); (Ž.S.); (P.P.); (H.E.); (Š.M.); (J.A.); (P.D.); (T.P.); (S.V.); (L.K.)
- Graduate School of Biomedicine, University of Ljubljana, 1000 Ljubljana, Slovenia
| | - Špela Malenšek
- Department of Synthetic Biology and Immunology, National Institute of Chemistry, 1000 Ljubljana, Slovenia; (T.F.); (V.F.); (S.O.); (Ž.S.); (P.P.); (H.E.); (Š.M.); (J.A.); (P.D.); (T.P.); (S.V.); (L.K.)
- Graduate School of Biomedicine, University of Ljubljana, 1000 Ljubljana, Slovenia
| | - Jana Aupič
- Department of Synthetic Biology and Immunology, National Institute of Chemistry, 1000 Ljubljana, Slovenia; (T.F.); (V.F.); (S.O.); (Ž.S.); (P.P.); (H.E.); (Š.M.); (J.A.); (P.D.); (T.P.); (S.V.); (L.K.)
| | - Petra Dekleva
- Department of Synthetic Biology and Immunology, National Institute of Chemistry, 1000 Ljubljana, Slovenia; (T.F.); (V.F.); (S.O.); (Ž.S.); (P.P.); (H.E.); (Š.M.); (J.A.); (P.D.); (T.P.); (S.V.); (L.K.)
- Graduate School of Biomedicine, University of Ljubljana, 1000 Ljubljana, Slovenia
| | - Tjaša Plaper
- Department of Synthetic Biology and Immunology, National Institute of Chemistry, 1000 Ljubljana, Slovenia; (T.F.); (V.F.); (S.O.); (Ž.S.); (P.P.); (H.E.); (Š.M.); (J.A.); (P.D.); (T.P.); (S.V.); (L.K.)
- Graduate School of Biomedicine, University of Ljubljana, 1000 Ljubljana, Slovenia
| | - Sara Vidmar
- Department of Synthetic Biology and Immunology, National Institute of Chemistry, 1000 Ljubljana, Slovenia; (T.F.); (V.F.); (S.O.); (Ž.S.); (P.P.); (H.E.); (Š.M.); (J.A.); (P.D.); (T.P.); (S.V.); (L.K.)
- Graduate School of Biomedicine, University of Ljubljana, 1000 Ljubljana, Slovenia
| | - Lucija Kadunc
- Department of Synthetic Biology and Immunology, National Institute of Chemistry, 1000 Ljubljana, Slovenia; (T.F.); (V.F.); (S.O.); (Ž.S.); (P.P.); (H.E.); (Š.M.); (J.A.); (P.D.); (T.P.); (S.V.); (L.K.)
| | - Mojca Benčina
- EN-FIST, Centre of Excellence, 1000 Ljubljana, Slovenia; (D.L.); (I.H.-B.); (M.M.-K.); (M.B.)
- Department of Synthetic Biology and Immunology, National Institute of Chemistry, 1000 Ljubljana, Slovenia; (T.F.); (V.F.); (S.O.); (Ž.S.); (P.P.); (H.E.); (Š.M.); (J.A.); (P.D.); (T.P.); (S.V.); (L.K.)
| | - Neža Omersa
- Department of Molecular Biology and Nanobiotechnology, National Institute of Chemistry, 1000 Ljubljana, Slovenia; (N.O.); (G.A.)
| | - Gregor Anderluh
- Department of Molecular Biology and Nanobiotechnology, National Institute of Chemistry, 1000 Ljubljana, Slovenia; (N.O.); (G.A.)
| | - Florence Pojer
- Protein Production and Structure Core Facility PTPSP- EPFL SV PTECH PTPSP, 1015 Lausanne, Switzerland; (F.P.); (K.L.); (D.H.); (B.E.C.)
| | - Kelvin Lau
- Protein Production and Structure Core Facility PTPSP- EPFL SV PTECH PTPSP, 1015 Lausanne, Switzerland; (F.P.); (K.L.); (D.H.); (B.E.C.)
| | - David Hacker
- Protein Production and Structure Core Facility PTPSP- EPFL SV PTECH PTPSP, 1015 Lausanne, Switzerland; (F.P.); (K.L.); (D.H.); (B.E.C.)
| | - Bruno E. Correia
- Protein Production and Structure Core Facility PTPSP- EPFL SV PTECH PTPSP, 1015 Lausanne, Switzerland; (F.P.); (K.L.); (D.H.); (B.E.C.)
| | - David Peterhoff
- Molecular Microbiology (Virology), Institute of Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany; (D.P.); (R.W.)
| | - Ralf Wagner
- Molecular Microbiology (Virology), Institute of Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany; (D.P.); (R.W.)
- Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany
| | - Valter Bergant
- Immunopathology of Virus Infections Laboratory, Institute of Virology, Technical University of Munich, 81675 Munich, Germany; (V.B.); (A.H.); (A.P.)
| | - Alexander Herrmann
- Immunopathology of Virus Infections Laboratory, Institute of Virology, Technical University of Munich, 81675 Munich, Germany; (V.B.); (A.H.); (A.P.)
| | - Andreas Pichlmair
- Immunopathology of Virus Infections Laboratory, Institute of Virology, Technical University of Munich, 81675 Munich, Germany; (V.B.); (A.H.); (A.P.)
- German Center for Infection Research (DZIF), Munich Partner Site, 38124 Braunschweig, Germany
| | - Roman Jerala
- EN-FIST, Centre of Excellence, 1000 Ljubljana, Slovenia; (D.L.); (I.H.-B.); (M.M.-K.); (M.B.)
- Department of Synthetic Biology and Immunology, National Institute of Chemistry, 1000 Ljubljana, Slovenia; (T.F.); (V.F.); (S.O.); (Ž.S.); (P.P.); (H.E.); (Š.M.); (J.A.); (P.D.); (T.P.); (S.V.); (L.K.)
- Correspondence:
| |
Collapse
|
12
|
Fougeroux C, Goksøyr L, Idorn M, Soroka V, Myeni SK, Dagil R, Janitzek CM, Søgaard M, Aves KL, Horsted EW, Erdoğan SM, Gustavsson T, Dorosz J, Clemmensen S, Fredsgaard L, Thrane S, Vidal-Calvo EE, Khalifé P, Hulen TM, Choudhary S, Theisen M, Singh SK, Garcia-Senosiain A, Van Oosten L, Pijlman G, Hierzberger B, Domeyer T, Nalewajek BW, Strøbæk A, Skrzypczak M, Andersson LF, Buus S, Buus AS, Christensen JP, Dalebout TJ, Iversen K, Harritshøj LH, Mordmüller B, Ullum H, Reinert LS, de Jongh WA, Kikkert M, Paludan SR, Theander TG, Nielsen MA, Salanti A, Sander AF. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity. Nat Commun 2021; 12:324. [PMID: 33436573 PMCID: PMC7804149 DOI: 10.1038/s41467-020-20251-8] [Citation(s) in RCA: 68] [Impact Index Per Article: 22.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2020] [Accepted: 11/23/2020] [Indexed: 01/29/2023] Open
Abstract
The rapid development of a SARS-CoV-2 vaccine is a global priority. Here, we develop two capsid-like particle (CLP)-based vaccines displaying the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. RBD antigens are displayed on AP205 CLPs through a split-protein Tag/Catcher, ensuring unidirectional and high-density display of RBD. Both soluble recombinant RBD and RBD displayed on CLPs bind the ACE2 receptor with nanomolar affinity. Mice are vaccinated with soluble RBD or CLP-displayed RBD, formulated in Squalene-Water-Emulsion. The RBD-CLP vaccines induce higher levels of serum anti-spike antibodies than the soluble RBD vaccines. Remarkably, one injection with our lead RBD-CLP vaccine in mice elicits virus neutralization antibody titers comparable to those found in patients that had recovered from COVID-19. Following booster vaccinations, the virus neutralization titers exceed those measured after natural infection, at serum dilutions above 1:10,000. Thus, the RBD-CLP vaccine is a highly promising candidate for preventing COVID-19.
Collapse
Affiliation(s)
| | - Louise Goksøyr
- AdaptVac Aps, 2970, Hørsholm, Denmark
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark
| | - Manja Idorn
- Department of Biomedicine, Aarhus University, 8000, Aarhus, Denmark
| | | | - Sebenzile K Myeni
- Department of Medical Microbiology, Leiden University Medical Center, ZA, Leiden, 2333, Netherlands
| | - Robert Dagil
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark
- VAR2pharmaceuticals, 2200, Copenhagen, Denmark
| | - Christoph M Janitzek
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark
| | - Max Søgaard
- ExpreS2ion Biotechnologies Aps, 2970, Hørsholm, Denmark
| | - Kara-Lee Aves
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark
| | - Emma W Horsted
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark
| | - Sayit Mahmut Erdoğan
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark
- Turkish Ministry of Agriculture and Forestry, 06800, Ankara, Turkey
| | - Tobias Gustavsson
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark
- VAR2pharmaceuticals, 2200, Copenhagen, Denmark
| | - Jerzy Dorosz
- ExpreS2ion Biotechnologies Aps, 2970, Hørsholm, Denmark
| | | | - Laurits Fredsgaard
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark
| | | | | | - Paul Khalifé
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark
| | - Thomas M Hulen
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark
| | - Swati Choudhary
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark
- VAR2pharmaceuticals, 2200, Copenhagen, Denmark
| | - Michael Theisen
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark
- Department for Congenital Disorders, Statens Serum Institute, 2300, Copenhagen, Denmark
| | - Susheel K Singh
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark
- Department for Congenital Disorders, Statens Serum Institute, 2300, Copenhagen, Denmark
| | - Asier Garcia-Senosiain
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark
- Department for Congenital Disorders, Statens Serum Institute, 2300, Copenhagen, Denmark
| | - Linda Van Oosten
- Department of Plant Sciences, Laboratory of Virology, 6700AA, Wageningen, Netherlands
| | - Gorben Pijlman
- Department of Plant Sciences, Laboratory of Virology, 6700AA, Wageningen, Netherlands
| | | | - Tanja Domeyer
- ExpreS2ion Biotechnologies Aps, 2970, Hørsholm, Denmark
| | | | | | | | | | - Søren Buus
- Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200, Copenhagen, Danmark
| | - Anette Stryhn Buus
- Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200, Copenhagen, Danmark
| | - Jan Pravsgaard Christensen
- Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200, Copenhagen, Danmark
| | - Tim J Dalebout
- Department of Medical Microbiology, Leiden University Medical Center, ZA, Leiden, 2333, Netherlands
| | - Kasper Iversen
- Department of Cardiology, Herlev Hospital, 2730, Herlev, Denmark
| | - Lene H Harritshøj
- Department of Clinical Immunology, Copenhagen University Hospital, 2100, Copenhagen, Denmark
| | - Benjamin Mordmüller
- Universitätsklinikum Tübingen, Institut für Tropenmedizin, 72074, Tübingen, Germany
- Centre de Recherches Médicales de Lambaréné, BP 242, Lambaréné, Gabon
| | - Henrik Ullum
- Department of Cardiology, Herlev Hospital, 2730, Herlev, Denmark
| | - Line S Reinert
- Department of Biomedicine, Aarhus University, 8000, Aarhus, Denmark
| | - Willem Adriaan de Jongh
- AdaptVac Aps, 2970, Hørsholm, Denmark
- ExpreS2ion Biotechnologies Aps, 2970, Hørsholm, Denmark
| | - Marjolein Kikkert
- Department of Medical Microbiology, Leiden University Medical Center, ZA, Leiden, 2333, Netherlands
| | - Søren R Paludan
- Department of Biomedicine, Aarhus University, 8000, Aarhus, Denmark
| | - Thor G Theander
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark
| | - Morten A Nielsen
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark.
| | - Ali Salanti
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark
- VAR2pharmaceuticals, 2200, Copenhagen, Denmark
| | - Adam F Sander
- AdaptVac Aps, 2970, Hørsholm, Denmark.
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, 2200, Copenhagen, Denmark.
| |
Collapse
|
13
|
Eskandari S, Good MF, Pandey M. Peptide-Protein Conjugation and Characterization to Develop Vaccines for Group A Streptococcus. Methods Mol Biol 2021; 2355:17-33. [PMID: 34386947 DOI: 10.1007/978-1-0716-1617-8_3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Peptide conjugates have been widely used for developing vaccines that prevent common bacterial infections for which peptides alone are either ineffective or provide only short-term protection. Among several carrier proteins, diphtheria toxoid and CRM197 (a genetically detoxified diphtheria toxin) are considered safe and have been used in several licensed vaccines. For developing a vaccine against group A streptococcus (GAS), antigens from conserved region of M protein and the IL-8 protease, SpyCEP, have been identified. In this chapter, we describe a method for producing peptide-conjugate subunit GAS vaccines, which involves maleimide conjugation of peptides to a carrier protein and their subsequent characterization.
Collapse
Affiliation(s)
| | - Michael F Good
- Institute for Glycomics, Griffith University, Southport, QLD, Australia
| | - Manisha Pandey
- Institute for Glycomics, Griffith University, Southport, QLD, Australia.
| |
Collapse
|
14
|
Robinson C, Gradinati V, Hamid F, Baehr C, Crouse B, Averick S, Kovaliov M, Harris D, Runyon S, Baruffaldi F, LeSage M, Comer S, Pravetoni M. Therapeutic and Prophylactic Vaccines to Counteract Fentanyl Use Disorders and Toxicity. J Med Chem 2020; 63:14647-14667. [PMID: 33215913 DOI: 10.1021/acs.jmedchem.0c01042] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The incidence of fatal overdoses has increased worldwide due to the widespread access to illicit fentanyl and its potent analogues. Vaccines offer a promising strategy to reduce the prevalence of opioid use disorders (OUDs) and to prevent toxicity from accidental and deliberate exposure to fentanyl and its derivatives. This study describes the development and characterization of vaccine formulations consisting of novel fentanyl-based haptens conjugated to carrier proteins. Vaccine efficacy was tested against opioid-induced behavior and toxicity in mice and rats challenged with fentanyl and its analogues. Prophylactic vaccination reduced fentanyl- and sufentanil-induced antinociception, respiratory depression, and bradycardia in mice and rats. Therapeutic vaccination also reduced fentanyl intravenous self-administration in rats. Because of their selectivity, vaccines did not interfere with the pharmacological effects of commonly used anesthetics nor with methadone, naloxone, oxycodone, or heroin. These preclinical data support the translation of vaccines as a viable strategy to counteract fentanyl use disorders and toxicity.
Collapse
Affiliation(s)
- Christine Robinson
- Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, United States
| | - Valeria Gradinati
- Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, United States
| | - Fatima Hamid
- Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, United States
| | - Carly Baehr
- Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, United States.,Department of Veterinary Population Medicine, University of Minnesota Veterinary School, Minneapolis, Minnesota 55455, United States
| | - Bethany Crouse
- Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, United States.,Department of Veterinary Population Medicine, University of Minnesota Veterinary School, Minneapolis, Minnesota 55455, United States
| | - Saadyah Averick
- Allegheny Health Network, Neuroscience Research Institute, Pittsburgh, Pennsylvania 15212, United States
| | - Marina Kovaliov
- Allegheny Health Network, Neuroscience Research Institute, Pittsburgh, Pennsylvania 15212, United States
| | - Danni Harris
- RTI International, Raleigh, North Carolina 27616, United States
| | - Scott Runyon
- RTI International, Raleigh, North Carolina 27616, United States
| | - Federico Baruffaldi
- Department of Medicine, Hennepin Healthcare Research Institute, Minneapolis, Minnesota 55415, United States
| | - Mark LeSage
- Department of Medicine, Hennepin Healthcare Research Institute, Minneapolis, Minnesota 55415, United States
| | - Sandra Comer
- Department of Psychiatry, Columbia University Irving Medical Center, and the New York State Psychiatric Institute, New York, New York 10027-6902, United States
| | - Marco Pravetoni
- Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, United States.,Center for Immunology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, United States
| |
Collapse
|
15
|
Aggregation by peptide conjugation rescues poor immunogenicity of the HA stem. PLoS One 2020; 15:e0241649. [PMID: 33137148 PMCID: PMC7605677 DOI: 10.1371/journal.pone.0241649] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2020] [Accepted: 10/16/2020] [Indexed: 11/19/2022] Open
Abstract
Influenza virus infection is a global public health threat. Current seasonal influenza vaccines are efficacious only when vaccine strains are matched with circulating strains. There is a critical need for developing "universal" vaccines that protect against all influenza viruses. HA stem is a promising target for developing broad-spectrum influenza vaccines due to its relatively conserved feature. However, HA stem is weakly immunogenic when administered alone in a soluble form. Several approaches have been employed to improve the immunogenicity of HA stem, including conjugation of HA stem with a highly immunogenic carrier protein or displaying HA stem on a nanoparticle scaffold. Converting a weakly immunologic protein into a multimer through aggregation can significantly enhance its immunogenicity, with some multimeric protein aggregates previously shown to be more immunogenic than their soluble counterparts in animal models. Here, we show that a chemically coupling a peptide derived from the head domain of PR8 HA (P35) with the poorly immunogenic HA stem protein results in aggregation of the HA stem which significantly increases stem-specific B cell responses following vaccination. Importantly, vaccination with this conjugate in the absence of adjuvant still induced robust B cell responses against stem in vivo. Improving HA stem immunogenicity by aggregation provides an alternative avenue to conjugation with exotic carrier proteins or nanoparticle formulation.
Collapse
|
16
|
Huang Q, Gao Q, Chai X, Ren W, Zhang G, Kong Y, Zhang Y, Gao J, Lei X, Ma L. A novel thrombin inhibitory peptide discovered from leech using affinity chromatography combined with ultra-high performance liquid chromatography-high resolution mass spectroscopy. J Chromatogr B Analyt Technol Biomed Life Sci 2020; 1151:122153. [PMID: 32512533 DOI: 10.1016/j.jchromb.2020.122153] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2020] [Revised: 04/21/2020] [Accepted: 05/09/2020] [Indexed: 02/08/2023]
Abstract
Thrombin (THR) inhibitors play an important role in the treatment of thrombotic diseases. This study established a THR-based bio-specific extraction coupled with affinity chromatography and ultra-high performance liquid chromatography-high resolution mass spectroscopy (UPLC-HR-MS) analysis method to screen and identify THR ligands in Leech. After evaluating the reliability of the screening method using positive control drug (hirudin), it was successfully used to screen the potential active constituents in leech. And a comprehensive analysis of the peptides in leech elution was performed by UPLC-HR-MS, a total of 34 peptides were identified. At the same time, anti-THR activity was explored and inferred by searching databases and published literature. As a result, six peptides were discovered to be potential active compounds in leech. Further, the six peptides were synthesized and in vitro enzymatic activity assay was performed. Finally, SYELPDGQVITIGNER was screened as an anti-THR peptide with an IC50 value of 255.75 µM and it was discovered for the first time from Whitmania pigra Whitman and Hirudo nipponica Whitman. The molecular docking study showed that THR inhibitory activity of the polypeptide was mainly attributed to the hydrogen bond interactions, van der Waals forces and electrostatic interactions interaction between polypeptide and THR. These results suggest that the polypeptide is a potential natural THR inhibitor that can be used as anticoagulant.
Collapse
Affiliation(s)
- Qiuyang Huang
- School of Traditional Chinese Medicine, Capital Medical University, Beijing 100069, China
| | - Qian Gao
- School of Traditional Chinese Medicine, Capital Medical University, Beijing 100069, China
| | - Xiaoxin Chai
- School of Traditional Chinese Medicine, Capital Medical University, Beijing 100069, China
| | - Wei Ren
- Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China
| | - Guifeng Zhang
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China
| | - Yingjun Kong
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China
| | - Yan Zhang
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China
| | - Jianping Gao
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China
| | - Xiongxin Lei
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China
| | - Li Ma
- School of Traditional Chinese Medicine, Capital Medical University, Beijing 100069, China.
| |
Collapse
|
17
|
Saylor K, Gillam F, Lohneis T, Zhang C. Designs of Antigen Structure and Composition for Improved Protein-Based Vaccine Efficacy. Front Immunol 2020; 11:283. [PMID: 32153587 PMCID: PMC7050619 DOI: 10.3389/fimmu.2020.00283] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2019] [Accepted: 02/04/2020] [Indexed: 12/19/2022] Open
Abstract
Today, vaccinologists have come to understand that the hallmark of any protective immune response is the antigen. However, it is not the whole antigen that dictates the immune response, but rather the various parts comprising the whole that are capable of influencing immunogenicity. Protein-based antigens hold particular importance within this structural approach to understanding immunity because, though different molecules can serve as antigens, only proteins are capable of inducing both cellular and humoral immunity. This fact, coupled with the versatility and customizability of proteins when considering vaccine design applications, makes protein-based vaccines (PBVs) one of today's most promising technologies for artificially inducing immunity. In this review, we follow the development of PBV technologies through time and discuss the antigen-specific receptors that are most critical to any immune response: pattern recognition receptors, B cell receptors, and T cell receptors. Knowledge of these receptors and their ligands has become exceptionally valuable in the field of vaccinology, where today it is possible to make drastic modifications to PBV structure, from primary to quaternary, in order to promote recognition of target epitopes, potentiate vaccine immunogenicity, and prevent antigen-associated complications. Additionally, these modifications have made it possible to control immune responses by modulating stability and targeting PBV to key immune cells. Consequently, careful consideration should be given to protein structure when designing PBVs in the future in order to potentiate PBV efficacy.
Collapse
Affiliation(s)
- Kyle Saylor
- Department of Biological Systems Engineering, Virginia Tech, Blacksburg, VA, United States
| | - Frank Gillam
- Department of Biological Systems Engineering, Virginia Tech, Blacksburg, VA, United States
- Locus Biosciences, Morrisville, NC, United States
| | - Taylor Lohneis
- Department of Biological Systems Engineering, Virginia Tech, Blacksburg, VA, United States
- BioPharmaceutical Technology Department, GlaxoSmithKline, Rockville, MD, United States
| | - Chenming Zhang
- Department of Biological Systems Engineering, Virginia Tech, Blacksburg, VA, United States
| |
Collapse
|
18
|
Ho JKT, Jeevan-Raj B, Netter HJ. Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms. Viruses 2020; 12:v12020126. [PMID: 31973017 PMCID: PMC7077199 DOI: 10.3390/v12020126] [Citation(s) in RCA: 55] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Revised: 01/13/2020] [Accepted: 01/13/2020] [Indexed: 12/15/2022] Open
Abstract
Hepatitis B remains one of the major global health problems more than 40 years after the identification of human hepatitis B virus (HBV) as the causative agent. A critical turning point in combating this virus was the development of a preventative vaccine composed of the HBV surface (envelope) protein (HBsAg) to reduce the risk of new infections. The isolation of HBsAg sub-viral particles (SVPs) from the blood of asymptomatic HBV carriers as antigens for the first-generation vaccines, followed by the development of recombinant HBsAg SVPs produced in yeast as the antigenic components of the second-generation vaccines, represent landmark advancements in biotechnology and medicine. The ability of the HBsAg SVPs to accept and present foreign antigenic sequences provides the basis of a chimeric particulate delivery platform, and resulted in the development of a vaccine against malaria (RTS,S/AS01, MosquirixTM), and various preclinical vaccine candidates to overcome infectious diseases for which there are no effective vaccines. Biomedical modifications of the HBsAg subunits allowed the identification of strategies to enhance the HBsAg SVP immunogenicity to build potent vaccines for preventative and possibly therapeutic applications. The review provides an overview of the formation and assembly of the HBsAg SVPs and highlights the utilization of the particles in key effective vaccines.
Collapse
Affiliation(s)
- Joan Kha-Tu Ho
- Victorian Infectious Diseases Reference Laboratory (VIDRL), Melbourne Health, The Peter Doherty Institute, Melbourne, Victoria 3000, Australia; (J.K.-T.H.); (B.J.-R.)
| | - Beena Jeevan-Raj
- Victorian Infectious Diseases Reference Laboratory (VIDRL), Melbourne Health, The Peter Doherty Institute, Melbourne, Victoria 3000, Australia; (J.K.-T.H.); (B.J.-R.)
| | - Hans-Jürgen Netter
- Victorian Infectious Diseases Reference Laboratory (VIDRL), Melbourne Health, The Peter Doherty Institute, Melbourne, Victoria 3000, Australia; (J.K.-T.H.); (B.J.-R.)
- Royal Melbourne Institute of Technology (RMIT) University, School of Science, Melbourne, Victoria 3001, Australia
- Correspondence:
| |
Collapse
|
19
|
Yadav R, Zhai L, Tumban E. Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today? Viruses 2019; 12:v12010018. [PMID: 31877975 PMCID: PMC7019592 DOI: 10.3390/v12010018] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2019] [Revised: 12/15/2019] [Accepted: 12/18/2019] [Indexed: 12/17/2022] Open
Abstract
Human papillomaviruses (HPVs) are the most common sexually transmitted infections worldwide. Ninety percent of infected individuals clear the infection within two years; however, in the remaining 10% of infected individuals, the infection(s) persists and ultimately leads to cancers (anogenital cancers and head and neck cancers) and genital warts. Fortunately, three prophylactic vaccines have been approved to protect against HPV infections. The most recent HPV vaccine, Gardasil-9 (a nonavalent vaccine), protects against seven HPV types associated with ~90% of cervical cancer and against two HPV types associated with ~90% genital warts with little cross-protection against non-vaccine HPV types. The current vaccines are based on virus-like particles (VLPs) derived from the major capsid protein, L1. The L1 protein is not conserved among HPV types. The minor capsid protein, L2, on the other hand, is highly conserved among HPV types and has been an alternative target antigen, for over two decades, to develop a broadly protective HPV vaccine. The L2 protein, unlike the L1, cannot form VLPs and as such, it is less immunogenic. This review summarizes current studies aimed at developing HPV L2 vaccines by multivalently displaying L2 peptides on VLPs derived from bacteriophages and eukaryotic viruses. Recent data show that a monovalent HPV L1 VLP as well as bivalent MS2 VLPs displaying HPV L2 peptides (representing amino acids 17–36 and/or consensus amino acids 69–86) elicit robust broadly protective antibodies against diverse HPV types (6/11/16/18/26/31/33/34/35/39/43/44/45/51/52/53/56/58/59/66/68/73) associated with cancers and genital warts. Thus, VLP-based L2 vaccines look promising and may be favorable, in the near future, over current L1-based HPV vaccines and should be explored further.
Collapse
Affiliation(s)
- Rashi Yadav
- Department of Biological Sciences, Michigan Technological University, Houghton, MI 49931, USA; (R.Y.); (L.Z.)
| | - Lukai Zhai
- Department of Biological Sciences, Michigan Technological University, Houghton, MI 49931, USA; (R.Y.); (L.Z.)
- Current address: Van Andel Research Institute, Grand Rapids, MI 49503, USA
| | - Ebenezer Tumban
- Department of Biological Sciences, Michigan Technological University, Houghton, MI 49931, USA; (R.Y.); (L.Z.)
- Correspondence: ; Tel.: +1-906-487-2256; Fax: +1-906-487-3167
| |
Collapse
|
20
|
Marini A, Zhou Y, Li Y, Taylor IJ, Leneghan DB, Jin J, Zaric M, Mekhaiel D, Long CA, Miura K, Biswas S. A Universal Plug-and-Display Vaccine Carrier Based on HBsAg VLP to Maximize Effective Antibody Response. Front Immunol 2019; 10:2931. [PMID: 31921185 PMCID: PMC6921968 DOI: 10.3389/fimmu.2019.02931] [Citation(s) in RCA: 46] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2019] [Accepted: 11/28/2019] [Indexed: 01/26/2023] Open
Abstract
Development of effective malaria vaccines requires delivery platforms to enhance the immunogenicity and efficacy of the target antigens. This is particularly challenging for transmission-blocking malaria vaccines (TBVs), and specifically for those based on the Pfs25 antigen, that need to elicit very high antibody titers to stop the parasite development in the mosquito host and its transmission. Presenting antigens to the immune system on virus-like particles (VLPs) is an efficient way to improve the quantity and quality of the immune response generated. Here we introduce for the first time a new VLP vaccine platform, based on the well-established hepatitis B surface antigen (HBsAg) fused to the SpyCatcher protein, so that the antigen of interest, linked to the SpyTag peptide, can be easily displayed on it (Plug-and-Display technology). As little as 10% of the SpyCatcher::HBsAg VLPs decorated with Pfs25::SpyTag (molar ratio) induces a higher antibody response and transmission-reducing activity in mice compared to the soluble protein, with 50 and 90% of the VLP coupled to the antigen further enhancing the response. Importantly, using this carrier that is a vaccine antigen itself could be beneficial, as we show that anti-HBsAg IgG antibodies are induced without interfering with the Pfs25-specific immune response generated. Furthermore, pre-existing anti-HBsAg immunity does not affect the antigen-specific response to Pfs25::SpyTag-SpyCatcher::HBsAg, suggesting that these VLPs can have a broad use as a vaccine platform.
Collapse
Affiliation(s)
- Arianna Marini
- Nuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford, United Kingdom
| | - Yu Zhou
- Nuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford, United Kingdom
| | - Yuanyuan Li
- Nuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford, United Kingdom
| | - Iona J. Taylor
- Nuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford, United Kingdom
| | - Darren B. Leneghan
- Nuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford, United Kingdom
| | - Jing Jin
- Nuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford, United Kingdom
| | - Marija Zaric
- Nuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford, United Kingdom
| | - David Mekhaiel
- Nuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford, United Kingdom
| | - Carole A. Long
- Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rockville, MD, United States
| | - Kazutoyo Miura
- Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rockville, MD, United States
| | - Sumi Biswas
- Nuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford, United Kingdom
| |
Collapse
|
21
|
Zeigler DF, Gage E, Roque R, Clegg CH. Epitope targeting with self-assembled peptide vaccines. NPJ Vaccines 2019; 4:30. [PMID: 31341647 PMCID: PMC6642127 DOI: 10.1038/s41541-019-0125-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2019] [Accepted: 06/26/2019] [Indexed: 12/16/2022] Open
Abstract
Nanoparticle-based delivery systems are being used to simplify and accelerate new vaccine development. Previously, we described the solid-phase synthesis of a 61-amino acid conjugate vaccine carrier comprising a α-helical domain followed by two universal T cell epitopes. Circular dichroism, analytical centrifugation, and dynamic light scattering indicate that this carrier forms coiled-coil nanoparticles. Here we expand the potential of this carrier by appending B cell epitopes to its amino acid sequence, thereby eliminating the need for traditional conjugation reactions. Peptides containing Tau or amyloid-β epitopes at either terminus assemble into ~20 nm particles and induce antibody responses in outbred mice. Vaccine function was verified in three experiments. The first targeted gonadotropin-releasing hormone, a 10-amino acid neuropeptide that regulates sexual development. Induction of peak antibody titers in male mice stimulated a dramatic loss in fertility and marked testis degeneration. The second experiment generated antibodies to an epitope on the murine IgE heavy chain analogous to human IgE sequence recognized by omalizumab, the first monoclonal antibody approved for the treatment of allergic asthma. Like omalizumab, the anti-IgE antibodies in immunized mice reduced the concentrations of circulating free IgE and prevented IgE-induced anaphylaxis. Finally, a peptide containing the highly conserved Helix A epitope within the influenza hemagglutinin stem domain induced antibodies that successfully protected mice against a lethal H1N1 challenge. These results establish the utility of a new vaccine platform for eliciting prophylactic and therapeutic antibodies to linear and helical B cell epitopes. Synthetic nanoparticles have the potential to be a simple, efficacious, and customizable platform for vaccine delivery. Christopher H. Clegg and colleagues include B cell epitopes on a self-assembling α-helical peptide nanoparticle carrier in order to elicit robust antibody generation. This novel vaccine platform is validated in vivo to produce physiologically-relevant antibodies in three different settings: an antibody-mediated ‘castration’ approach (anti-gonadotropin-releasing hormone), depletion of IgE (by generation of anti-IgE), and finally production of antibodies to a conserved H1N1 influenza epitope that mediates a protective effect in mice.
Collapse
Affiliation(s)
- David F Zeigler
- 1TRIA Bioscience Corp, Suite 260, 1616 Eastlake Avenue East, Seattle, WA 98102 USA
| | - Emily Gage
- 1TRIA Bioscience Corp, Suite 260, 1616 Eastlake Avenue East, Seattle, WA 98102 USA
| | - Richard Roque
- 1TRIA Bioscience Corp, Suite 260, 1616 Eastlake Avenue East, Seattle, WA 98102 USA.,2Present Address: MedImmune, One MedImmune Way, Gaithersburg, MD 20878 USA
| | - Christopher H Clegg
- 1TRIA Bioscience Corp, Suite 260, 1616 Eastlake Avenue East, Seattle, WA 98102 USA
| |
Collapse
|
22
|
Zeigler DF, Roque R, Clegg CH. Optimization of a multivalent peptide vaccine for nicotine addiction. Vaccine 2019; 37:1584-1590. [PMID: 30772068 DOI: 10.1016/j.vaccine.2019.02.003] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2018] [Revised: 01/15/2019] [Accepted: 02/03/2019] [Indexed: 12/20/2022]
Abstract
We have been optimizing the design of a conjugate vaccine for nicotine addiction that employs a peptide-based hapten carrier. This peptide, which is produced by solid-phase protein synthesis, contains B cell and T cell epitope domains and eliminates the non-relevant, but highly immunogenic sequences in microbial carriers. In this report, the amino acid sequences in the T cell domain were optimized for improved vaccine activity and multivalent formulations containing structurally distinct haptens were tested for the induction of additive antibody responses. Trivalent vaccines produced antibody concentrations in mice that were 100 times greater than the amount of nicotine measured in smokers, and significantly reduced acute nicotine toxicity in rats. Two additional features were explored that distinguish the peptide from traditional recombinant carriers. The first is the minimal induction of an anti-carrier response, which can suppress nicotine vaccine activity. The second employs solid-phase synthesis to manufacture haptenated peptide. This approach obviates conventional conjugation chemistries and streamlines production of a more potent vaccine antigen.
Collapse
Affiliation(s)
- David F Zeigler
- TRIA Bioscience Corp, Suite 260, 1616 Eastlake Ave East, Seattle, WA 98102 USA
| | - Richard Roque
- TRIA Bioscience Corp, Suite 260, 1616 Eastlake Ave East, Seattle, WA 98102 USA.
| | - Christopher H Clegg
- TRIA Bioscience Corp, Suite 260, 1616 Eastlake Ave East, Seattle, WA 98102 USA.
| |
Collapse
|
23
|
Dai LX, Yang J, Liu JM, Huang S, Wang BN, Li H, Yang J, Zhao ZY, Cao K, Li MY. Adenovirus-Mediated CRM197 Sensitizes Human Glioma Cells to Gemcitabine by the Mitochondrial Pathway. Cancer Biother Radiopharm 2018; 34:171-180. [PMID: 30585767 DOI: 10.1089/cbr.2017.2363] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
PURPOSE The cross-reacting material 197 (CRM197) is a mutation of the diphtheria toxin. The protein of CRM197 was used successfully for the therapy of various tumors in the recent studies. In this study, the recombinant adenoviruses containing the CRM197gene(AdCRM197) were used to enhance the cellar toxicity of gemcitabine in human glioma U87, U251, and H4 cells. PROCEDURES MTT assay and flow cytometric analysis were performed to test the apoptosis of the U87, U251 and H4 cells with the combined treatment of AdCRM197 plus gemcitabine. Western blotting analyses were carried out to detect the cell apoptosis of the mitochondrial pathway. And the xenograft nude mice were used to observe the enhanced antitumor effect of AdCRM197 in vivo. RESULTS AdCRM197 sensitizes human glioma cells to gemcitabine in vitro by the mitochondrial pathway. Tumor volume was inhibited and survival time was prolonged in the U251 or U87 xenografted nude mice with gemcitabine plus AdCRM197. The enhanced antitumor effect of AdCRM197 was also detected by the immunohistochemical analyses and TUNEL staining. CONCLUSION The authors found that AdCRM197 sensitized the human glioma to gemcitabine not only in vitro but also in vivo. They provide the first evidence that adenovirus-mediated CRM197 may be a potential chemosensitizing agent for the treatment of cancer. The diphtheria toxin is of great toxicity that even one molecule of diphtheria toxin is enough to kill one cell. However, because of the high toxicity, the diphtheria toxin would kill the packing cells when it is being packaged into the recombinant viruses. Therefore, the diphtheria toxin is hard to be used in the gene therapy for virus vectors. The cross-reacting material 197 (CRM197) is a mutation of the diphtheria toxin. Unlike DTA, CRM197 exhibit a weak toxicity. The week toxicity of CRM197 is a good feature for the virus packaging. In the present study, we used a recombinant adenovirus which carried a CRM197 gene (AdCRM197) to enhance the cellar toxicity of gemcitabine in human glioma cells.
Collapse
Affiliation(s)
- Lv-Xia Dai
- 1 Department of Microbiology, West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University , Chengdu, China .,2 Department of Pathogen Biology, Chengdu Medical College , Chengdu, China
| | - Jing Yang
- 3 Department of Infectious Disease, Renmin Hospital, Hubei University of Medicine , Shiyan, China
| | - Jian-Min Liu
- 4 Department of Neurosurgery, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine , Guangzhou, China
| | - Sizhou Huang
- 2 Department of Pathogen Biology, Chengdu Medical College , Chengdu, China
| | - Bao-Ning Wang
- 1 Department of Microbiology, West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University , Chengdu, China
| | - Hong Li
- 5 West China Second University Hospital, Sichuan University , Chengdu, China
| | - Jie Yang
- 6 Department of Neurology, The First Affiliated Hospital of Chengdu Medical College , Chengdu, China
| | - Zhong-Yi Zhao
- 1 Department of Microbiology, West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University , Chengdu, China
| | - Kang Cao
- 2 Department of Pathogen Biology, Chengdu Medical College , Chengdu, China
| | - Ming-Yuan Li
- 1 Department of Microbiology, West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University , Chengdu, China
| |
Collapse
|
24
|
Kimishima A, Olson ME, Natori Y, Janda KD. Efficient Syntheses of Cocaine Vaccines and Their in Vivo Evaluation. ACS Med Chem Lett 2018; 9:411-416. [PMID: 29795751 PMCID: PMC5949726 DOI: 10.1021/acsmedchemlett.8b00051] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2018] [Accepted: 04/16/2018] [Indexed: 01/03/2023] Open
Abstract
![]()
Though cocaine abuse
and addiction continue to have serious implications
for health and society, no FDA-approved interventions have been developed.
Anticocaine conjugate vaccines offer an attractive opportunity for
addiction treatment; however, vaccines have thus far failed in clinical
trials. As a result, anticocaine vaccines must be further optimized
to achieve clinical translation. Herein, we report a study on the
relationship between vaccine efficacy and hapten stability toward
hydrolysis. Two haptens developed by our laboratory, GND and GNE,
were conjugated to tetanus toxoid (TT) and formulated with alum and
cytosine-guanine oligodeoxynucleotide 1826 (CpG ODN 1826) adjuvants,
the optimal formulation in anticocaine vaccine design. GND, a diamide,
is more hydrolytically stable than GNE, a monoamide, toward butyrylcholinesterases.
Ultimately, both vaccines induced antibodies with high affinity for
cocaine. In hyperlocomotion testing, GND-TT and GNE-TT vaccinated
mice exhibited a robust blockade of cocaine’s stimulatory effects
at all tested doses. Overall, antibodies raised against both haptens
were highly effective in protecting mice from cocaine-induced psychostimulation.
Collapse
Affiliation(s)
- Atsushi Kimishima
- Department of Chemistry, Department of Immunology and Microbial Science, The Skaggs Institute for Chemical Biology, and WIRM Institute for Research and Medicine, The Scripps Research Institute, La Jolla, California 92037, United States
| | - Margaret E. Olson
- Department of Chemistry, Department of Immunology and Microbial Science, The Skaggs Institute for Chemical Biology, and WIRM Institute for Research and Medicine, The Scripps Research Institute, La Jolla, California 92037, United States
| | - Yoshihiro Natori
- Department of Chemistry, Department of Immunology and Microbial Science, The Skaggs Institute for Chemical Biology, and WIRM Institute for Research and Medicine, The Scripps Research Institute, La Jolla, California 92037, United States
| | - Kim D. Janda
- Department of Chemistry, Department of Immunology and Microbial Science, The Skaggs Institute for Chemical Biology, and WIRM Institute for Research and Medicine, The Scripps Research Institute, La Jolla, California 92037, United States
| |
Collapse
|
25
|
Sieser JE, Maloney MT, Chisowa E, Brenek SJ, Monfette S, Salisbury JJ, Do NM, Singer RA. Ir-Catalyzed Borylation as an Efficient Route to a Nicotine Hapten. Org Process Res Dev 2018. [DOI: 10.1021/acs.oprd.8b00053] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Janice E. Sieser
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Mark T. Maloney
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Esmort Chisowa
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Steven J. Brenek
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Sebastien Monfette
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - John J. Salisbury
- Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Nga M. Do
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Robert A. Singer
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
26
|
Peng CJ, Chen HL, Chiu CH, Fang JM. Site-Selective Functionalization of Flagellin by Steric Self-Protection: A Strategy To Facilitate Flagellin as a Self-Adjuvanting Carrier in Conjugate Vaccine. Chembiochem 2018; 19:805-814. [PMID: 29377518 DOI: 10.1002/cbic.201700634] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2017] [Indexed: 01/18/2023]
Abstract
Flagellin (FliC) can act as a carrier protein in the preparation of conjugate vaccines to elicit a T-cell-dependent immune response and as an intrinsic adjuvant to activate the toll-like receptor 5 (TLR5) to enhance vaccine potency. To enable the use of FliC as a self-adjuvanting carrier, an effective method for site-selective modification (SSM) of pertinent amino-acid residues in the D2 and D3 domains of FliC is explored without excessive modification of the D0 and D1 domains, which are responsible for activating and binding with TLR5. In highly concentrated Na2 SO4 solution, FliC monomers form flagellar filaments, in which the D0 and D1 domains are situated inside the tubular structure. Thus, the lysine residues (K219, K224, K324, and K331) in the D2 and D3 domains of flagellin are selectively modified by a diazo-transfer reaction with imidazole-1-sulfonyl azide. The sites with azido modification are confirmed by MALDI-TOF-MS, ESI-TOF-MS, and LC-MS/MS analyses along with label-free quantitation. The azido-modified filament dissolves to give FliC monomers, which can conjugate with alkyne-hinged saccharides by the click reaction. Transmission electron microscopy imaging, dynamic light scattering measurements, and the secreted embryonic alkaline phosphatase reporter assay indicate that the modified FliC monomers retain the ability either to bind with TLR5 or to reassemble into filaments. Overall, this study establishes a feasible method for the SSM of FliC by steric self-protection of the D0 and D1 domains.
Collapse
Affiliation(s)
- Chi-Jiun Peng
- Department of Chemistry, National Taiwan University, 1, Sec. 4, Roosevelt Road, Taipei, 10617, Taiwan
| | - Hsiu-Ling Chen
- Molecular Infectious Disease Research Center, Chang Gung Memorial Hospital, 5, Fuxing Street, Guishan District, Taoyuan, 33302, Taiwan
| | - Cheng-Hsun Chiu
- Molecular Infectious Disease Research Center, Chang Gung Memorial Hospital, 5, Fuxing Street, Guishan District, Taoyuan, 33302, Taiwan
- Department of Pediatrics, Chang Gung Children's Hospital, 5, Fuxing Street, Guishan District, Taoyuan, 33302, Taiwan
- Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, 259 Wenhua 1st Road, Guishan District, Taoyuan, 33302, Taiwan
| | - Jim-Min Fang
- Department of Chemistry, National Taiwan University, 1, Sec. 4, Roosevelt Road, Taipei, 10617, Taiwan
- The Genomics Research Center, Academia Sinica, 128, Sec. 2, Academia Road, Taipei, 11529, Taiwan
| |
Collapse
|
27
|
Tashani M, Heron L, Wong M, Rashid H, Booy R. Tetanus-diphtheria-pertussis vaccine may suppress the immune response to subsequent immunization with pneumococcal CRM197-conjugate vaccine (coadministered with quadrivalent meningococcal TT-conjugate vaccine): a randomized, controlled trial⋆. J Travel Med 2017; 24:3092398. [PMID: 28375507 DOI: 10.1093/jtm/tax006] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 01/20/2017] [Indexed: 11/13/2022]
Abstract
BACKGROUND : Due to their antigenic similarities, there is a potential for immunological interaction between tetanus/diphtheria-containing vaccines and carrier proteins presented on conjugate vaccines. The interaction could, unpredictably, result in either enhancement or suppression of the immune response to conjugate vaccines if they are injected soon after or concurrently with diphtheria or tetanus toxoid. We examined this interaction among adult Australian travellers before attending the Hajj pilgrimage of 2015. METHODS We randomly assigned each participant to one of three vaccination schedules. Group A received tetanus, diphtheria and acellular pertussis vaccine (Tdap) 3-4 weeks before receiving CRM197-conjugated 13-valent pneumococcal vaccine (PCV13) coadministered with TT-conjugated quadrivalent meningococcal vaccine (MCV4). Group B received all three vaccines concurrently. Group C received PCV13 and MCV4 3-4 weeks before Tdap. Blood samples collected at baseline, at each vaccination visit and 3-4 weeks after vaccination were tested for the pneumococcal opsonophagocytic assay (OPA). RESULTS A total of 166 participants aged 18-64 (median 42) years were recruited, 159 completed the study. Compared with the other groups, Group A had significantly ( P < 0.05) lower geometric mean titres (GMTs) post-vaccination in seven serotypes of PCV13 (1, 3, 4, 5, 14, 18C and 9V). Additionally, Group A had lower frequency of serorises (≥ 4-fold rise in OPA titres) in serotype5 (79%, p = 0.01) and 18C (73.5%, p = 0.06); whereas Groups B and C had significantly lower frequencies of serorises in Serotype 4 (82%) and 6A (73.5%), respectively. No statistically significant difference was detected across the three groups in frequencies achieving OPA titre ≥ 1:8 post-vaccination. CONCLUSIONS Tdap vaccination 3-4 weeks before administration of PCV13 and MCV4 significantly reduced the GMTs to seven of the 13 pneumococcal serotypes in adults. If multiple vaccination is required before travel, deferring tetanus/diphtheria until after administering the conjugate vaccine is recommended to avoid immune interference.
Collapse
Affiliation(s)
- Mohamed Tashani
- National Centre for Immunisation Research and Surveillance (NCIRS), The Children's Hospital at Westmead, NSW, Australia.,Discipline of Paediatrics and Child Health, Sydney Medical School, University of Sydney, NSW, Australia
| | - Leon Heron
- National Centre for Immunisation Research and Surveillance (NCIRS), The Children's Hospital at Westmead, NSW, Australia.,Kids Research Institute, The Children's Hospital at Westmead, NSW, Australia
| | - Melanie Wong
- Department of Immunology, The Children's Hospital at Westmead, Westmead, NSW, Australia
| | - Harunor Rashid
- National Centre for Immunisation Research and Surveillance (NCIRS), The Children's Hospital at Westmead, NSW, Australia.,Discipline of Paediatrics and Child Health, Sydney Medical School, University of Sydney, NSW, Australia.,Marie Bashir Institute for Infectious Diseases and Biosecurity, School of Biological Sciences and Sydney Medical School, University of Sydney, Sydney, NSW, Australia
| | - Robert Booy
- National Centre for Immunisation Research and Surveillance (NCIRS), The Children's Hospital at Westmead, NSW, Australia.,Discipline of Paediatrics and Child Health, Sydney Medical School, University of Sydney, NSW, Australia.,Marie Bashir Institute for Infectious Diseases and Biosecurity, School of Biological Sciences and Sydney Medical School, University of Sydney, Sydney, NSW, Australia.,WHO Collaborating Centre for Mass Gatherings and High Consequence/High Visibility Events, Flinders University, Adelaide, Australia
| |
Collapse
|
28
|
Kimishima A, Wenthur CJ, Zhou B, Janda KD. An Advance in Prescription Opioid Vaccines: Overdose Mortality Reduction and Extraordinary Alteration of Drug Half-Life. ACS Chem Biol 2017; 12:36-40. [PMID: 28103678 DOI: 10.1021/acschembio.6b00977] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Prescription opioids (POs) such as oxycodone and hydrocodone are highly effective medications for pain management, yet they also present a substantial risk for abuse and addiction. The consumption of POs has been escalating worldwide, resulting in tens of thousands of deaths due to overdose each year. Pharmacokinetic strategies based upon vaccination present an attractive avenue to suppress PO abuse. Herein, the preparation of two active PO vaccines is described that were found to elicit high-affinity antiopioid antibodies through a structurally congruent drug-hapten design. Administration of these vaccines resulted in a significant blockade of opioid analgesic activity, along with an unprecedented increase in drug serum half-life and protection against lethal overdose.
Collapse
Affiliation(s)
- Atsushi Kimishima
- Departments
of Chemistry and Immunology, The Skaggs Institute for Chemical Biology,
Worm Institute for Research and Medicine (WIRM), The Scripps Research Institute, La Jolla, California 92037, United States
| | - Cody J. Wenthur
- Departments
of Chemistry and Immunology, The Skaggs Institute for Chemical Biology,
Worm Institute for Research and Medicine (WIRM), The Scripps Research Institute, La Jolla, California 92037, United States
| | - Bin Zhou
- Departments
of Chemistry and Immunology, The Skaggs Institute for Chemical Biology,
Worm Institute for Research and Medicine (WIRM), The Scripps Research Institute, La Jolla, California 92037, United States
| | - Kim D. Janda
- Departments
of Chemistry and Immunology, The Skaggs Institute for Chemical Biology,
Worm Institute for Research and Medicine (WIRM), The Scripps Research Institute, La Jolla, California 92037, United States
| |
Collapse
|
29
|
Saupe F, Reichel M, Huijbers EJM, Femel J, Markgren PO, Andersson CE, Deindl S, Danielson UH, Hellman LT, Olsson AK. Development of a novel therapeutic vaccine carrier that sustains high antibody titers against several targets simultaneously. FASEB J 2016; 31:1204-1214. [PMID: 27993994 DOI: 10.1096/fj.201600820r] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2016] [Accepted: 12/06/2016] [Indexed: 01/10/2023]
Abstract
With the aim to improve the efficacy of therapeutic vaccines that target self-antigens, we have developed a novel fusion protein vaccine on the basis of the C-terminal multimerizing end of the variable lymphocyte receptor B (VLRB), the Ig equivalent in jawless fishes. Recombinant vaccines were produced in Escherichia coli by fusing the VLRB sequence to 4 different cancer-associated target molecules. The anti-self-immune response generated in mice that were vaccinated with VLRB vaccines was compared with the response in mice that received vaccines that contained bacterial thioredoxin (TRX), previously identified as an efficient carrier. The anti-self-Abs were analyzed with respect to titers, binding properties, and duration of response. VLRB-vaccinated mice displayed a 2- to 10-fold increase in anti-self-Ab titers and a substantial decrease in Abs against the foreign part of the fusion protein compared with the response in TRX-vaccinated mice (P < 0.01). VLRB-generated Ab response had duration similar to the corresponding TRX-generated Abs, but displayed a higher diversity in binding characteristics. Of importance, VLRB vaccines could sustain an immune response against several targets simultaneously. VLRB vaccines fulfill several key criteria for an efficient therapeutic vaccine that targets self-antigens as a result of its small size, its multimerizing capacity, and nonexposed foreign sequences in the fusion protein.-Saupe, F., Reichel, M., Huijbers, E. J. M., Femel, J., Markgren, P.-O., Andersson, C. E., Deindl, S., Danielson, U. H., Hellman, L. T., Olsson, A.-K. Development of a novel therapeutic vaccine carrier that sustains high antibody titers against several targets simultaneously.
Collapse
Affiliation(s)
- Falk Saupe
- Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
| | - Matthias Reichel
- Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
| | - Elisabeth J M Huijbers
- Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
| | - Julia Femel
- Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
| | - Per-Olof Markgren
- Department of Chemistry-BMC, Biomedical Center, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
| | - C Evalena Andersson
- Department of Cell and Molecular Biology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
| | - Sebastian Deindl
- Department of Cell and Molecular Biology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
| | - U Helena Danielson
- Department of Chemistry-BMC, Biomedical Center, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
| | - Lars T Hellman
- Department of Cell and Molecular Biology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
| | - Anna-Karin Olsson
- Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden;
| |
Collapse
|